women with any recognized form of heart disease within 2 years before the index birth. Data sets were linked using unique encoded identifiers and analyzed at the Institute for Clinical Evaluative Sciences. Institutional review board approval was granted by the Research Ethics Board of Sunnybrook Health Sciences Centre. Patients did not need to provide informed consent because data were deidentified.
Exposures and Outcomes
The main exposure at each woman's first delivery was 1 of 4 possible states: (1) PTB at 23 to 36 weeks' gestation with concomitant severe SGA birth weight under the fifth percentile for sex and gestational age 8 (PTB-SGA); (2) PTB at 23
to 36 weeks' gestation without severe SGA; (3) term birth with severe SGA; or (4) neither PTB nor SGA (the reference). There were 3 composite study outcomes: (1) hospitalization for heart failure or an atrial or ventricular dysrhythmia or all-cause mortality; (2) hospitalization for heart failure or an atrial or ventricular dysrhythmia; and (3) hospitalization for heart failure or an atrial or ventricular dysrhythmia or coronary artery disease (eTable in the Supplement). To minimize the immediate effect of the index pregnancy (eg, preeclampsia) or delivery (eg, iatrogenic fluid overload) on the risk of related cardiac events, study outcomes were assessed starting at 30 days after the index birth date. Details on cause-specific mortality were not available. The administrative data diagnostic codes used herein have largely been validated (eTable in the Supplement).
Data Analysis
Multivariable Cox proportional hazard models were used to generate hazard ratios (HRs) and 95% confidence intervals, with censoring at the end of the study period (March 31, 2016) or death (for composite outcomes 2 and 3 only). Hazard ratios were first adjusted for maternal age, income quintile, and preeclampsia/eclampsia (each at the index birth), as well as diabetes, chronic hypertension, obesity, dyslipidemia, drug dependence or smoking, and kidney disease (each within 24 months before the index birth date) (model 1). Hazard ratios were further adjusted for diabetes, chronic hypertension, obesity, dyslipidemia, drug dependence or smoking, and kidney disease, time-varying from the index birth date onward (model 2). Births with a congenital or chromosomal anomaly were then excluded from model 2, as they are more prone to be SGA and PTB and might, therefore, obscure any association between PTB-SGA and maternal cardiac disease. Statistical analyses were performed using SAS version 9.4 (SAS Institute), with significance set at a P value of less than .05.
Results
There were 710 501 singleton live births included, of which 619 311 (87.2%) were term birth without severe SGA, 43 240 (6.1%) were term birth with severe SGA, 45 134 (6.3%) were PTB without severe SGA, and 2816 (0.4%) were PTB-SGA ( Table 1) . At the index delivery, mothers with a PTB-SGA infant had more chronic hypertension than women with neither PTB nor SGA and more preeclampsia as well (Table 1) . Dyslipidemia, kidney disease, and South Asian origin were more prevalent among the former group of women. The median follow-up of the mothers was about 7.5 years ( Table 1) .
Women with a PTB-SGA infant were most likely to experience the composite outcome of hospitalization for heart failure, atrial or ventricular dysrhythmia, or death ( Figure) . Relative to having a term birth infant without severe SGA, the corresponding crude HR was 2.79 (95% CI, 1.85-4.21) among those with PTB-SGA ( Table 2 ). The HRs were somewhat reduced on adjusting for baseline covariates (model 1 in Table 2 ) and further attenuated by adding the time-varying covariates after the index delivery (model 2 in Table 2 ). Excluding births with a congenital or chromosomal anomaly, the adjusted HR in model 2 for the composite of heart failure, dysrhythmia, or death was largely unchanged among women with PTB-SGA (HR, 1.66; 95% CI, 1.05-2.62).
For the composite cardiac outcome of heart failure or atrial or ventricular dysrhythmia, the HR was significantly higher in women with a PTB-SGA birth but markedly attenuated on adjusting for risk factors before and after delivery ( Table 2) . A similar finding was seen for the composite outcome of hospitalization for heart failure, an atrial or ventricular dysrhythmia, or coronary artery disease ( Table 2) .
Discussion
Although this is the first study to directly assess the association of PTB-SGA and cardiac disease or death, to our knowledge, related studies support the current findings. Among 70 182 parous women in the Nurses' Health Study II 3 who
were followed for a median of 32 years, the adjusted HRs for myocardial infarction or stroke was 1.42 (95% CI, 1.16-1.72) in those with vs without PTB at less than 37 weeks and 2.01 (95% CI, 1.47-2.75) among women with very PTB at less than 32 weeks. In a Scottish data-linkage cohort study, the risk of ischemic heart disease was greatest among women who had preeclampsia with an infant both SGA and born preterm. 
Key Points
Question Are women with an infant born preterm and concomitantly are severely small for gestational age at higher risk of premature heart disease or death?
Findings This population-based retrospective cohort study comprised 710 501 singleton live births. Relative to infants who were not born preterm or were not severely small for gestational weight, the adjusted hazard ratio of the composite outcome of heart failure, dysrhythmia, or death was 1.66 (95% CI, 1.09-2.52) in women with a prior child who was born preterm and was severely small for gestational weight.
Meaning Women with an infant born preterm and severely small for gestational weight may be at higher risk for premature cardiac disease or death.
We adjusted for preeclampsia and still found that mothers who had a PTB-SGA infant were at higher risk of cardiac disease or death. Among 3225 Norwegian women who underwent standardized measurements of blood pressure, serum lipids, and body mass index (calculated as weight in kilograms divided by height in meters squared) before and after pregnancy, the association between preeclampsia and postpregnancy cardiovascular risk was partly due to prepregnancy risk factors. 10 It is unlikely that having a PTB-SGA infant causes future heart disease or death in the mother.
Rather, the same factors that predispose severe placental vascular disease to develop in a woman, 1 and hence PTB-SGA, also predispose myocardial dysfunction and coronary artery disease to prematurely develop. 5 As seen elsewhere, 3 this point is underscored by the observed reduction in the HR once postpregnancy risk factors were added to model 2. Direct assessment of myocardial function before and after pregnancy and its changes over time might improve our understanding of the apparent associations between placental vascular disease, PTB-SGA, and a woman's future risk of cardiac disease, especially in those with recurrent PTB-SGA. The reasons for spontaneous vs clinician-initiated PTB should also be evaluated, as the latter are more likely due to preeclampsia and poor fetal growth arising from placental vascular disease. 11 We used a more pathological cut-point of less than the fifth percentile to denote SGA. 1 At the more standard tenth percentile cut-point, 8, 9 many more women would qualify as having a PTB-SGA birth, but the resulting change to the current study outcomes is unknown.
Strengths and Limitations
We included more than 700 000 women in a universal health care setting. Mothers with prior cardiac disease were excluded from this cohort, and we accounted for some risk factors for PTB and SGA. In the study period, there were no notable changes in Ontario in the nature of cardiac disease diagnosis or physician reimbursement. The median duration of follow-up was about 7.5 years, which is not long enough for adverse outcome events to develop. Furthermore, as there were only 8 events of heart failure or a dysrhythmia among women with PTB-SGA, analysis of this outcome was likely statistically underpowered and perhaps not generalizable. Another limitation was lack of availability of echocardiographic assessment of left ventricular function or electrocardiographic determination of electrical activity. Our data were limited to hospitalized cardiac events, so out-of-hospital sudden cardiac death might only be indirectly captured under all-cause mortality. A pregnancy affected by severe placental vascular disease may result in fetal growth restriction and stillbirth; yet, our study was limited to live births. Women who experience a stillbirth may be especially at high future risk for cardiac disease.
12,13 Finally, there was likely residual confounding The maternal composite cardiac outcomes were hospitalization for heart failure, atrial or ventricular dysrhythmia, or death. Data are presented for all singleton live births from 23 to 42 weeks' gestation, and assessment of the study outcome started at 30 days after the index birth date. PTB indicates preterm birth at 23 to 36 weeks' gestation; SGA, small for gestational weight below the fifth percentile. 
Conclusions
Women who gave birth to an infant with PTB-SGA were at subsequent high risk of premature heart disease or death. This association was attenuated by classic cardiometabolic risk factors assessed before and after the index delivery. A clear understanding of the causes of death in women with prior PTB-SGA is needed, especially given that about two thirds of events in the main composite outcome were deaths. It should also be determined if cardiometabolic modification in women with PTB-SGA can reduce their risk of premature heart disease and death.
